This study evaluated sixteen canine nasal carcinoma and five normal nasal epithelium samples for expression and phosphorylation of known targets of toceranib [vascular endothelial growth factor receptor-2 (VEGR2), platelet derived growth factor alpha (PDGFR-a), platelet derived growth factor receptor beta (PDGFR-b), and stem cell factor receptor (c- iv
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Chapter 1-Introduction
Epithelial tumors, including adenocarcinoma, squamous cell carcinoma, and undifferentiated carcinoma, comprise nearly two-thirds of canine intra-nasal neoplasia.
1,2 These tumors are characterized by progressive local invasion and a low metastatic rate at the time of initial diagnosis, but may be as high as 40-50% at the time of death. 3 The cause of death in most patients is typically attributable to extensive primary disease rather than the presence of metastasis. Owing to this biologic behavior, external beam radiation therapy is the treatment of choice for canine intranasal tumors. Radiation therapy substantially improves survival, with median survival times of 7-23 months compared to 3 months for those patients that do not receive any form of treatment. [4] [5] [6] [7] Despite most dogs experiencing a favorable response to treatment, the majority of dogs treated with radiation therapy will experience tumor recurrence and suffer from progressive disease. In lieu of radiation therapy or when tumor recurrence is documented after radiation therapy, some owners may elect to pursue other treatment options such as chemotherapy.
Protein kinases are normal regulators of cell signaling that act through phosphorylation of other proteins and are stimulated by growth factors. Protein kinases can be expressed on the cell surface, cytoplasm, or even the nucleus. Toceranib phosphate (Palladiaâ, Pfizer Animal Health,
Madison, NJ, USA) is an FDA-approved canine drug that is a multi-kinase inhibitor that was developed to inhibit stem cell factor (c-KIT), a receptor tyrosine kinase (RTK) that is mutated in approximately 30% of canine mast cell tumors. 8 Multi-kinase inhibitors like toceranib work by blocking the ability of the kinase to bind ATP, as this is necessary for donating the phosphate group that phosphorylates the tyrosine kinase as well as downstream targets. The first clinical evaluation of toceranib in veterinary medicine was a phase I clinical trial evaluating safety and activity of the drug in dogs with a variety of tumor types. Mast cell tumors exhibited the highest frequency of response, but evidence for anti-tumor activity of toceranib was found in 54% of other treated cases including patients with carcinomas, sarcomas, melanoma, and multiple myeloma. 9 More recently, efficacy of toceranib phosphate has been retrospectively evaluated in a variety of solid tumor types, including nasal carcinomas. 10 Dogs receiving toceranib in this study exhibited a resolution of clinical signs, with one dog having an objectively measured complete response and another with stable disease, indicating toceranib phosphate may possess a role in the treatment of canine nasal carcinomas. Toceranib phosphate inhibits the activity of several RTKs linked to cancer biology including: vascular endothelial growth factor receptor 2 (VEGFR2), platelet derived growth factor receptor a (PDGFR-a), platelet derived growth factor receptor b (PDGFR-b), FMS-like tyrosine kinase 3 (FLT-3), colony stimulating factor receptor 1 (CSFR1), and stem cell factor receptor (c-KIT). 11 With this spectrum of inhibition, toceranib can act as an oral anti-angiogenic agent in those tumors that exhibit angiogenic RTKs such as VEGFR2, PDGFR-a, and PDGFR-b. 9, 12 Several RTK targets of toceranib expressed by canine nasal carcinomas are responsible for angiogenic sprouting and vascular maturation, both defined processes in vasculogenesis and angiogenesis that are imperative for tumor growth. 9, [12] [13] [14] In one report of 187 dogs with nasal carcinoma, VEGFR was detected in 84.5%, PDGFR-a in 71.1%, and PDGFR-b in 39.6% of tumors by immunohistochemistry. 13 While VEGFR was expressed in the majority of these canine nasal carcinomas, another report showed that 91.7% of epithelial nasal tumors also expressed the VEGF ligand. 14 Additionally, one report of dogs with solid tumors treated with toceranib identified significantly increased plasma VEGF level, a surrogate marker for VEGFR2 inhibition, denoting a possible anti-angiogenic effect. 15 Although potential RTK targets are present in canine nasal carcinomas, it is not known whether their constitutive phosphorylation is a direct underlying mechanism of toceranib's activity.
Epidermal growth factor receptor expression has been noted in a variety of canine tumors including transitional cell carcinoma, mammary carcinomas, gliomas, and pulmonary adenocarcinoma. [16] [17] [18] [19] Canine nasal carcinomas have also been shown to express epidermal growth factor receptor 1 (EGFR1) in 55% of tumors. 14 (nucleus, cytoplasm, or membrane) was averaged and if the value was higher than threshold, the cell was considered positive. Tumor stroma staining between non-staining neoplastic cells was also identified.
The percentage of neoplastic cells with positive immunoreactivity were scored according to the following: <5% = 0, 5-25% = 1, 26-50% = 2, and >50% = 3. Cytoplasmic (C), nuclear (N), membranous (M), and stromal (S) staining locations were also identified.
RNA isolation and RT-PCR
Total RNA from normal nasal tissue and carcinomas was obtained using the RNeasy Sequence alignments between canine RT-PCR products and known mammalian RTK sequences were constructed using BLASTÒ (National Center for Biotechnology Information, U.S National Library of Medicine).
Cell lysate preparation and phosphoprotein arrays
The Proteome Profilerä Human Phospho-RTK Array Kit (R&D Systems, Minneapolis, MN) was utilized to evaluate in situ phosphorylation of 49 different RTKs in nasal carcinoma and normal nasal epithelium samples, an assay previously utilized in canine studies. 11, 28 To prepare lysates, 50 mg milligrams of frozen tissue (normal nasal epithelium or nasal carcinoma) was ground with a liquid nitrogen-cooled mortar and pestle. The powdered tissue was resuspended in a lysis buffer (Lysis Buffer 17, R&D Systems, Minneapolis, MN) supplemented with 10ug/ml pepstatin, 10ug/ml leupeptin, and 10ug/ml aprotinin. The samples were rocked at 4°C for 30 minutes followed by centrifugation at 14,000 x g for 5 minutes. After completion, the supernatant was collected and the protein concentration was quantitated by the Bradford method (Bio-Rad, Hercules, CA). The phosphoprotein arrays were performed according to manufacturer's instructions using 300µg of protein lysate.
Phosphoproteins in nasal tissue samples were detected using a series of 49 specific capture antibodies that were pre-spotted in duplicate on nitrocellulose membranes by the kit Organization's histological classification of tumors of the respiratory system of domestic animals. 29 Adenocarcinoma encompassed 50% (n=8) of the tumors while transitional (n=4) and undifferentiated (n=4) nasal carcinomas each comprised 25% of the samples.
Immunohistochemistry
Sixteen nasal carcinoma tissue samples were evaluated for expression of RTKs of interest (Table 3 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Successful extraction of mRNA was obtained from all normal nasal and nasal carcinoma samples (Table 3. 2). Messenger RNA for c-KIT, PDGFR-b, and VEFGR2 was present in all sixteen tumors assessed; however, messenger RNA for PDGFR-a and EGFR1 was detected in only 15/16 (93.7%) samples. Messenger RNA for all RTKs were detected in normal nasal tissue.
Phosphoprotein Arrays
The phosphorylation status of forty-nine RTKs was assessed in sixteen nasal carcinoma and five normal nasal samples [ Table 3 .3 and Figure 3 .2]. Specific RTKs that were phosphorylated in >50% of tumors were Insulin-R (68.7%), EGFR1 (62.5%) and ROR2 (56.2%).
Phosphorylated RTKs in 25-50% of tumors were ALK (43.7%), RYK (37.5%), DTK (31.3%),
and Tie-1 (25%). Five normal nasal epithelium samples showed phosphorylation of Insulin R in 80% of samples, whereas phosphorylation of EGFR1, RYK, and ROR2 was identified in 60% of samples assessed. None of the nasal carcinoma or normal nasal epithelium samples had phosphorylation of VEGFR2, PDGFR-a, PDGFR-b, or c-KIT. The number (n) of the most common phosphorylated receptor tyrosine kinases (RTK) from sixteen canine nasal carcinoma samples evaluated by The Proteome Profilerä Human Phospho-RTK Array Kit. Multiple RTK targets of toceranib, particularly PDGFR-b, play crucial roles in the tumor microenvironment (TME) and their presence is documented by strong stromal expression. 30, 31 Stromal expression of PDGFR-b was present in all samples analyzed in this study whereas previous studies have shown only 60.9% of samples to have stromal staining for PDGFR-b. 13 The development and function of vessels in the TME rely heavily on PDGFR-b and inhibition of this RTK in the TME has been documented in some human solid tumors and may represent an indirect target for toceranib in canine nasal carcinomas. 30, 32, 33 Interestingly, VEGFR2 and PDGFR-a were not expressed in the tumor stroma in this study; however, PDGFR-a was shown to have nuclear localization. Nuclear localized RTKs have been shown to bypass standard signal transduction and respond to stimuli through transcriptional and translational regulation of target genes. 34 Nuclear localized RTKs, such as PDGFR-a, have been observed in highly proliferative normal tissues and neoplastic tissues that have an elevated signaling for cell growth, survival and differentiation. [34] [35] [36] [37] [38] The identified nuclear localization of PDGFR-a in nasal carcinoma tissues in this study may suggest that it has important implication in the development of this cancer;
however, further investigation into its role is warranted.
Aberrant function of EGFR1 has been implicated as an important oncogenic driver in a number of human cancers and the results of this study suggest that EGFR1's noted phosphorylation in over half of the nasal carcinoma samples may represent a possible role in tumorigenesis. 20, [39] [40] [41] Nearly all the samples analyzed in this study showed EGFR1's presence at the protein and messenger RNA level in comparison to a previously noted 55% of canine nasal carcinomas and 74% of human nasopharyngeal carcinomas. 14, 42 The discrepancy between the number of samples exhibiting phosphorylation and protein/messenger RNA expression in this study may tell us that while EGFR1 is expressed in most canine nasal carcinomas, only a subset may be in a persistently phosphorylated state. In addition to EGFR1 phosphorylation by nasal carcinomas, normal nasal epithelium evaluated within this study was shown to have high EGFR1 This study's descriptive design imparts various limitations including small study size, tumor heterogeneity, and tumor sample size. The small study size represents only a limited spectrum of the population of dogs afflicted by nasal carcinomas and evaluating a larger number of nasal carcinoma samples would allow for applicability of these results with more certainty.
As with many tumors, nasal carcinomas are heterogeneous in their composition and the tumor sample sizes in this study were small due to collection methodology. The combination of tumor heterogeneity and small sample size presents the possibility of misrepresenting true RTK phosphorylation and expression in the samples analyzed due to heterogeneous RTK distribution.
Chapter 5 -Conclusions
Major RTK targets of toceranib were not phosphorylated in the canine nasal carcinomas 
